Role of pan immune inflammatory value in the evaluation of hepatosteatosis in children and adolescents with obesity

Abstract

Objectives Inflammation is a feature of non-alcoholic fatty liver disease progression and plays an important role in hepatic steatosis and fibrosis. Since there are no studies in the literature showing the relationship between hepatosteatosis with the systemic immune-inflammation index (SII) and pan-immune inflammation value (PIV), we aimed to evaluate the relationship between these biomarkers and hepatosteatosis in childhood. Methods We included 133 consecutive obese children and adolescents aged 6–18 years into this single-center, retrospective, and cross-sectional study. Anthropometric, physical examination, radiological and laboratory data were obtained and recorded from the file records of each case. Results When we grouped the patient population according to the grade of hepatosteatosis, there was a statistically significant difference between the groups in terms of SII and PIV values (p<0.05, for both). In the analyzes performed to identify independent predictors of hepatosteatosis pubertal status (p=0.019) and PIV value (p<0.001) were found to be significant as independent predictors. Moreover, in the analysis performed to predict severity of hepatic steatosis, regression analysis was performed by dividing the groups into groups with and without severe adiposity. As a result of this analysis, HOMA-IR (p=0.019) and PIV value (p=0.028) were found to be significant in the prediction of severe hepatic adiposity. Conclusions Our findings showed that increased PIV levels were associated with the presence and severity of hepatic steatosis, but not with SII.

Associations between pan-immune-inflammation value and abdominal aortic calcification: a cross-sectional study

“…retrospectively analyzed the association between increased PIV and adverse outcomes, including worse overall survival (HR: 4.46, 95%CI: 2.22-8.99) and progression-free survival (HR: 2.03, 95% CI: 1.08-3.80), besides, resistance to platinum-based chemotherapy in patients with advanced triple-negative breast cancer ( 20 ). Furthermore, PIV has also been discovered as a novel biomarker in reflecting the association between inflammation and noncancer diseases, such as in hypertension, heart failure, myocardial infarction, kidney disease, frailty, and hepatic steatosis ( 13 , 24 – 28 ). Similarly, elevated PIV level correlated with the presence and severity of these noncancerous conditions.…”

“…Recent years, the focus of PIV-related research has mainly centered on its implications for the prognosis and therapeutic outcomes in oncological patients (11,12,(18)(19)(20)(21)(22)(23) (20). Furthermore, PIV has also been discovered as a novel biomarker in reflecting the association between inflammation and noncancer diseases, such as in hypertension, heart failure, myocardial infarction, kidney disease, frailty, and hepatic steatosis (13,(24)(25)(26)(27)(28). Similarly, elevated PIV level correlated with the presence and severity of these noncancerous conditions.…”

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis

“…12 PIV was initially developed for the prognostic stratification of patients with advanced colorectal cancer, and further developed as a promising prognostic tool in a variety of solid tumors and in other inflammation-and immune-related diseases. [12][13][14][15][16][17][18][19] PIV has also been preliminarily investigated as a biomarker in BC patients 18,20 ; however, no data are available about the potential prognostic significance of PIV in aTNBC patients.…”